Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.
Sarwar M, Semenas J, Miftakhova R, Simoulis A, Robinson B, Gjörloff Wingren A, Mongan NP, Heery DM, Johnsson H, Abrahamsson PA, Dizeyi N, Luo J, Persson JL.
Sarwar M, et al. Among authors: gjorloff wingren a.
Oncotarget. 2016 Sep 27;7(39):63065-63081. doi: 10.18632/oncotarget.11757.
Oncotarget. 2016.
PMID: 27588408
Free PMC article.